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Human b2-Glycoprotein I Binds to Endothelial Cells Through
a Cluster of Lysine Residues That Are Critical for Anionic
Phospholipid Binding and Offers Epitopes for
Anti-b2-Glycoprotein I Antibodies1,2
N. Del Papa,* Y. H. Sheng,† E. Raschi,* D. A. Kandiah,† A. Tincani,‡ M. A. Khamashta,§
T. Atsumi,§ G. R. V. Hughes,§ K. Ichikawa,¶ T. Koike,¶ G. Balestrieri,‡ S. A. Krilis,†
and P. L. Meroni3*
b2-Glycoprotein I (b2GPI) is a phospholipid-binding protein recognized by serum autoantibodies from the anti-phospholipid
syndrome both in cardiolipin- and b2GPI-coated plates. We found that: 1) recombinant wild-type b2GPI bound to HUVEC and
was recognized by both human monoclonal IgM and affinity-purified polyclonal IgG anti-b2GPI anti-phospholipid syndrome Abs;
and 2) a single amino acid change from Lys286 to Glu significantly reduced endothelial adhesion. Double and triple mutants (from
Lys284,287 to Glu284,287, from Lys286,287 to Glu286,287, and from Lys284,286,287 to Glu284,286,287) completely abolished endothelial
binding. A synthetic peptide (P1) spanning the sequence Glu274–Cys288 of the b2GPI fifth domain still displayed endothelial
adhesion. Another peptide (P8), identical with P1 except that Cys281 and Cys288 were substituted with serine residues, did not bind
to HUVEC. Anti-b2GPI Abs, once bound to P1 adhered to HUVEC, induced E-selectin expression and up-regulated IL-6 secre-
tion. Control experiments conducted with irrelevant Abs as well as with the P8 peptide did not show any endothelial Ab binding
nor E-selectin and IL-6 modulation. Our results suggest that: 1) b2GPI binds to endothelial cells through its fifth domain; 2) the
major phospholipid-binding site that mediates the binding to anionic phospholipids is also involved in endothelial binding; 3)
HUVEC provide a suitable surface for b2GPI binding comparable to that displayed by anionic phospholipids dried on microtiter
wells; and 4) the formation of the complex between b2GPI and the specific Abs leads to endothelial activation in vitro. The
Journal of Immunology, 1998, 160: 5572–5578.
H uman b2-glycoprotein I (b2GPI)4 is a phospholipid(PL)-binding protein that is required for the binding ofautoantibodies in sera from patients with the anti-
phospholipid syndrome (APS) to cardiolipin (CL)-coated plates
(1–3). It is not yet known whether anti-b2GPI Abs recognize
epitopes displayed by native b2GPI when available at increased
density or new epitopes expressed after binding of the molecule to
negatively charged structures (4–6). Anti-b2GPI Abs may be pu-
rified from both primary and secondary APS sera. Such serum
anti-b2GPI Abs have been found to be associated with thrombotic
events and/or fetal loss, suggesting a potential pathogenic role in
APS (7–13).
b2GPI is composed of five highly conserved subunits called
sushi domains or complement control protein repeats (14, 15). The
major PL-binding site on b2GPI has been identified as a highly
positively charged amino acid sequence, Lys282-Asn-Lys-Glu-
Lys-Lys287, in the fifth domain of the molecule (16–20).
b2GPI binds not only to negatively charged substances such as
PL (21), heparin (22), and lipoproteins (23), but also to cell mem-
branes such as activated platelets (24–26). Recently, several
groups demonstrated that b2GPI is able to bind to resting endo-
thelial cells and to be recognized by monoclonal and polyclonal
anti-b2GPI Abs (27–30). While platelet binding has been related
to the large expression of anionic PL on platelet cell membranes
after activation, a comparable phenomenon is unlikely on resting
endothelial cells, which do not display such PL distribution
changes (31).
The aim of the present study was to investigate whether b2GPI
binds to endothelial cells through the same amino acid sequence
that is involved in binding to anionic phospholipids. If b2GPI-
endothelial cell binding mirrors that found in the solid phase CL
assay, it is reasonable to assume that endothelial cells can represent
one of the natural structures to which b2GPI binds, offering suit-
able epitopes to circulating anti-b2GPI Abs. In this regard, it is
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useful to point out that Ab binding to b2GPI adhered on endothe-
lial membranes has been shown to cause, at least in vitro, cell
activation that induces the expression of proinflammatory and
proadhesive molecules (27, 30, 32).
Materials and Methods
Native and wild-type b2GPI
Native b2GPI was purified from human serum and characterized as pre-
viously described (13, 33). Wild-type synthetic molecule was obtained by
insertion of cDNA for human b2GPI into the baculovirus viral DNA
BacPAK 6 for expression in insect cells (Spodoptera frugiperda (Sf)) (20).
Wild-type b2GPI was purified from supernatants of transfected insect cells,
its purity assessed by SDS-PAGE, and subjected to N-terminal amino acid
sequencing as detailed previously (20). As well as native b2GPI, the wild-
type molecule: 1) displayed PL-binding properties, since it bound to CL-
coated plates and inhibited the binding of native iodinated b2GPI to CL in
solid phase; 2) expressed epitopes recognized by affinity-purified anti-
b2GPI Abs in an anti-b2GPI ELISA; and 3) displayed cofactor activity,
since it was recognized by anti-b2GPI Abs in a CL-ELISA (20).
b2GPI mutants
Site-directed mutagenesis was performed to assess the role of individual
amino acids in the Lys282-Lys287 loop for the PL-binding and anti-b2GPI
activity as detailed (20). Four mutants were obtained: 1k, with a single
amino acid change from Lys286 to Glu; 2k and 2ka, with a double amino
acid change (from Lys286,287 to Glu286,287 and from Lys284,287 to Glu284,287
respectively); and 3k, with a triple amino acid change (from Lys 284,286,287
to Glu 284,286,287). In comparison to native and wild-type b2GPI, mutant 1k
displayed 1) reduced PL-binding activity, 2) lower cofactor activity for
anti-b2GPI Abs in a CL-ELISA, and 3) decreased inhibition of the binding
of iodinated native b2GPI to CL-coated plates. Double or triple mutants
2k, 2ka, and 3k lost the PL-binding activity and did not display any co-
factor activity for anti-b2GPI Abs in CL ELISA or the ability to inhibit
iodinated native b2GPI binding to CL. While mutations in the Lys282-
Lys287 loop altered the properties of the PL-binding site, they did not affect
the recognition of all the mutants by purified anti-b2GPI Abs in an anti-
b2GPI ELISA (20).
b2GPI synthetic peptides
The peptides (P1, P8) spanning the residues of the PL-binding site of the
fifth domain of b2GPI, were synthesized by the Queensland Institute of
Medical Research (Brisbane, Australia) as previously described (17, 34).
Residue numbers in the native protein and amino acid sequence were 274–
288, GDKVSFFCKNKEKKC for P1, and 274–288, GDKVSFFSKNKE
KKS for P8, respectively (34). The residue GDKVSFF has been shown to
be recognized by anti-b2GPI GR1D5 mAb, while the residue
CKNKEKKC displays PL-binding site activity (34). Accordingly, both P1
and P8 were able to inhibit, in a dose-dependent manner, the binding of
anti-b2GPI GR1D5 mAb to b2GPI. However, P8 did not display any co-
factor activity, since the substitution of C281 and C288 with serine residues
affected the PL-binding activity (34).
Human monoclonal anti-b2GPI Abs
Three human mAbs of the IgM isotype derived from patients with APS
were used. GR1D5 and TM1G2 have been characterized previously as
reacting with human b2GPI. TM1B9, which did not display reactivity to
b2GPI, was used as a negative control. The characterization of the mAbs
had been previously reported in detail (35).
Detection and affinity purification of anti-b2GPI Abs
Anti-b2GPI Abs were detected by a solid phase ELISA as described (10,
13, 27, 30). Sera from two patients with a primary APS were collected, and
the whole IgG fractions were purified on protein G-Sepharose (HiTrap
Protein G, Pharmacia Biotech Europe Uppsala, Sweden) as previously re-
ported (13). The anti-b2GPI Abs were then affinity purified using solid
phase, linked b2GPI as previously described (13). The characteristics of
the patients and of the affinity-purified preparations have been reported in
detail previously (13, 30).
Endothelial cell culture
HUVEC were isolated from normal term umbilical cord vein by collage-
nase perfusion and cultured as previously reported (27). Endothelial cells
were grown in standard medium, washed three times with HBSS (Flow
Laboratories, Irvine, U.K.) (200 ml/well), and cultured for 5 h in serum-free
medium (HyQ-CCMTM 1, HyClone Laboratories, Logan, UT) to remove
adherent serum proteins including b2GPI supplied by bovine serum
present in the culture medium.
Binding of b2GPI and synthetic peptides to endothelial cells
A cell-ELISA was performed to determine whether any of the anti-b2GPI
Abs (monoclonal and polyclonal) bound to endothelial monolayers through
the adherent b2GPI and synthetic peptides. Serum-free endothelial cell
cultures grown to confluence in 96-well microtiter plates were incubated
with: 1) human native b2GPI (100, 50, and 25 nM); 2) recombinant wild-
type b2GPI (100, 50, and 25 nM); 3) recombinant b2GPI mutants (100, 50,
and 25 nM); 4) synthetic peptides (up to 1000 mM); and 5) with serum-free
medium for 1 h at 37°C. The unoccupied binding sites in the wells were
then blocked with HBSS-0.5% gelatin for 1 h at 37°C, and the plates where
washed twice with HBSS. Affinity-purified anti-b2GPI IgG and the IgM
mAb preparations, ranging from 100 to 3.1 mg/ml, were added to the wells.
After a 2-h incubation, followed by three washes, the plates were incubated
with alkaline phosphatase-conjugated goat anti-human IgG or IgM (Sigma
Chemical, St. Louis, MO) for 90 min. After four washes, chromogenic
substrate (50 ml of p-nitrophenylphosphate (1 mg/ml)) in 10% diethanol-
amine buffer, pH 9.8, was added to each well and incubated for 30 min. OD
was read at 405 nm (Titertek Multiskan ELISA reader; Lobsystein, Fin-
land) as previously described (27).
Endothelial E-selectin expression
E-selectin expression was evaluated by a cell ELISA as previously de-
scribed (27, 30). Briefly, confluent HUVEC monolayers in serum-free me-
dium were incubated with human purified b2GPI (100 nM) or synthetic
peptides (800 mM) for 1 h at 37°C. The cultures were then incubated with:
1) human IgM anti-b2GPI mAb GR1D5 (at final protein concentrations
ranging from 3.1 to 100 mg/ml); 2) human irrelevant IgM mAb TM1B9
(100 mg/ml); 3) affinity-purified IgG anti-b2GPI (100 mg/ml); or 4) normal
human serum (NHS) IgG (100 mg/ml) in a final volume of 200 ml for 4 h
at 37°C. After incubation, the cells were washed twice with RPMI 1640
(Life Technologies, Grand Island, NY), 2.5% FCS (Flow Laboratories),
and incubated for 60 min at room temperature with 100 ml/well of murine
monoclonal IgG specific for E-selectin at a final dilution of 1/1000 (Sero-
tec, Kidlington, Oxford, U.K., catalogue no. MCA883). After three more
washes, the cells were fixed with 3% paraformaldehyde for 15 min at room
temperature. Cells were then washed three times and incubated for another
60 min at room temperature with 100 ml of peroxidase-conjugated goat
anti-mouse IgG (Cappel, Cochranville, PA). After four washes with RPMI
1640, 2.5% FCS, and one more with PBS alone, 100 ml of orthophenylen-
diamine (0.5 mg/ml in sodium citrate buffer (1021 M), pH 5, plus 0.01%
H2O2) were added. The OD values were read at 450 nm, after a 30-min
incubation, by a semiautomatic reader (Titertek Multiskan). The following
control cultures were also performed: 1) HUVEC incubated with human
purified b2GPI (100 nM) or with synthetic peptides (up to 1600 mM)
alone; and 2) HUVEC in serum-free medium alone. As a positive control,
additional cultures were incubated in the presence of 50 U/ml of human
IL-1b (British Bio-Technology Products, Oxford, U.K.) using the same
experimental conditions.
IL-6 production by endothelial cultures
To investigate endothelial IL-6 secretion, HUVEC cultures in serum-free
medium were incubated with: 1) medium alone, 2) human purified b2GPI
(100 nM), or 3) synthetic peptides (P1 or P8; 800 mM) for 1 h at 37°C.
After two washes with HBSS, the human IgM GR1D5 or the irrelevant
control TM1B9 (100 mg/ml) were added to the cultures at a final volume
of 200 ml/well. As a positive control, HUVEC in serum-free medium were
incubated with 50 U/ml of human rIL-1b, and the experiment was per-
formed as described above. After the incubation period (6 h at 37°C), the
plates were centrifuged at 800 rpm at 4°C for 10 min, and the cell-free
supernatant was removed for IL-6 determination.
IL-6 was measured as hybridoma growth factor (HGF) on the indicator
7TD1 cell line, as previously reported (30).
Results
Binding of native and wild-type b2GPI and mutants of b2GPI
to HUVEC monolayer in vitro
HUVEC cultured in serum-free medium were incubated with: 1)
purified native human b2GPI, 2) recombinant wild-type b2GPI,
and 3) 1k, 2k, 2ka, and 3k mutants of b2GPI at several concen-
trations. Endothelium-bound b2GPI was then evaluated as anti-
b2GPI (GR1D5) mAb binding to the monolayers. In contrast to the
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irrelevant human IgM mAb (TM1B9), GR1D5 anti-b2GPI human
IgM mAb recognizes both human native and recombinant wild-
type b2GPI on HUVEC monolayers (Table I). When endothelial
cells were incubated with the 1k mutant, GR1D5 binding values
were 58% of those obtained in the presence of recombinant wild-
type b2GPI. No mAb binding was observed when HUVEC were
incubated in the presence of mutants lacking the PL-binding prop-
erties (2k, 2ka, and 3k) or with serum-free medium. Comparable
results have been obtained with another human anti-b2GPI
TM1G2 mAb (data not shown). All of the human mAbs were used
at a final protein concentration of 100 mg/ml, which was shown to
display optimal binding (see Fig. 1). GR1D5 mAb binding to
HUVEC was dependent on the final amount of native b2GPI, of
recombinant molecules, or of peptides, respectively, added to the
cultures (Table I). Wild-type b2GPI supported Ab binding to en-
dothelial cells at concentrations of 50 and 25 nM, higher than for
purified human native b2GPI.
Binding of synthetic b2GPI peptides to endothelial monolayers
HUVEC cultured in serum-free medium were incubated with a
synthetic peptide (P1) possessing the amino acid sequence that
binds to negatively charged PL. The synthetic peptide (P8) does
not bind to PL and was used as a negative control. The human
anti-b2GPI IgM (GR1D5) mAb that recognizes the common res-
idue GDKVSFF was used to identify the peptides on the endothe-
lial monolayer. Figure 2 shows that GR1D5 was able to bind
HUVEC in the presence of P1. Endothelial GR1D5 binding was
directly related to the amount of P1 added to the cultures, display-
ing maximum binding at a concentration of 800 mM. No binding
was found with HUVEC incubated with the control peptide (P8) or
with HUVEC cultured in serum-free medium alone. Comparable
experiments performed with the irrelevant mAb TM1B9 displayed
negligible endothelial binding. Control endothelial monolayers
cultured in the presence of the optimal human native b2GPI con-
centration (100 nM) (30) displayed a clear GR1D5 binding (920 6
32, mean OD values [ 3 1023] 6 SD of three determinations).
Two affinity-purified anti-b2GPI polyclonal IgG Abs (patients
M.B. and B.A.) were able to recognize human b2GPI and syn-
thetic peptide P1. Table II shows the binding of the affinity-puri-
fied anti-b2GPI IgG to endothelial monolayers in the absence or
presence of human b2GPI or in the presence of increasing con-
centrations of P1 and P8 peptides. It can be seen that affinity-
purified anti-b2GPI IgG preparations did not bind to endothelial
monolayers cultured in serum-free medium and that the addition of
human native b2GPI restored the binding. The same IgG fractions
exhibited a dose-dependent binding to P1 but not to P8 on HUVEC
monolayers. Control human IgG did not change their background
FIGURE 1. Endothelial GR1D5 binding at serial protein concentrations
in the presence of native b2GPI (100 nM; h) or synthetic peptides P1 (800
mM; o) or P8 (800 mM; p). Values are expressed as OD (3 1023) values;
mean 6 SD of triplicate experiments. Negligible binding was found by
incubating HUVEC with the control mAb TM1B9 or with cells in serum-
free medium (data not shown).
FIGURE 2. Recognition of adhered synthetic b2GPI peptides to
HUVEC by the human anti-b2GPI mAb GR1D5 (100 mg/ml) and the
control mAb TM1B9 (100 mg/ml). GR1D5 binding to serum-free HUVEC
in the presence of synthetic peptides P1 () or P8 () (0 to 1000 mM) is
shown. Parallel experiments were conducted with TM1B9 in the presence
of the same peptides, P1 (V) or P8 (h). mAb binding is expressed as OD
(3 1023) mean values 6 SD of triplicate experiments.
Table I. Binding of GR1D5 anti-b2GPI mAb to endothelial cells
incubated in the presence of native b2GPI, recombinant wild-type
b2GPI, or recombinant b2GPI mutantsa
Protein Concentrations (nM)
100 50 25
Native b2GPI 849 6 91b 594 6 49 176 6 65
Wild-type b2GPI 915 6 54 933 6 38 329 6 86
Mutants of b2GPI
1K 528 6 84 437 6 93 297 6 69
2K 275 6 67 167 6 35 191 6 25
2Ka 202 6 54 179 6 32 214 6 45
3K 130 6 25 157 6 32 117 6 51
a GR1D5 anti-b2GPI mAb was used at 100 mg/ml. GR1D5 anti-b2GPI mAb
incubated with HUVEC in serum-free medium without exogenous b2GPI gave the
following background binding values: 134 6 21 (mean of triplicate experiment 6
SD). Comparable experiments performed with the control human IgM mAb (TM1B9)
did not show any significant endothelial binding.
b OD values (31023) are expressed as mean 6 SD of triplicate experiments.
5574 b2GPI BINDS ENDOTHELIUM VIA THE PHOSPHOLIPID-BINDING SITE
endothelial binding under any of the experimental conditions em-
ployed. Table III shows the dose-dependent binding of affinity-
purified anti-b2GPI IgG to HUVEC monolayers incubated in the
presence od optimal concentrations of native b2GPI or P1 or P8
peptides. Control NHS IgG did not display any endothelial binding
even at highest protein concentration (100 mg/ml).
E-selectin expression induced by Ab binding to synthetic
peptides on HUVEC
Since it has been demonstrated recently that both polyclonal and
monoclonal anti-b2GPI Abs can up-regulate adhesion molecule
expression after endothelial binding (27, 30), we investigated
whether affinity-purified IgG and human anti-b2GPI mAbs di-
rected against endothelium-bound P1 (and P8) were able to mod-
ulate E-selectin expression on HUVEC. To this end, HUVEC in
serum-free medium were incubated with either native human
b2GPI (100 nM) or peptide P1 (800 mM) or P8 (800 mM). E-
selectin expression was then measured in the presence of mAbs, of
affinity-purified anti-b2GPI IgG, or of the respective controls. En-
dothelial cultures treated with 50 U/ml of human rIL-1b were used
as positive control for E-selectin expression. Table IV shows that,
in contrast to IL-1b, both monoclonal and polyclonal anti-b2GPI
Abs did not induce any E-selectin expression on HUVEC under
serum-free medium conditions. The addition of human purified
b2GPI as well as P1 (but not P8) induced E-selectin. As shown in
Figure 3, GR1D5 induced E-selectin expression even at protein
concentrations as low as 12.5 mg/ml. Parallel experiments with
serial protein concentrations of affinity-purified IgG fractions
showed that E-selectin was up-regulated at concentrations as high
FIGURE 3. Anti-b2GPI mAb GR1D5 recognizes the synthetic peptide
P1 bound to HUVEC and induces E-selectin expression in a dose-depen-
dent manner. GR1D5 was used at serial protein concentrations (100–3.1
mg/ml). E-selectin expression was investigated in HUVEC cultured in the
presence of human b2GPI (100 nM; h), or synthetic peptides P1 (800 mM;
o) or P8 (800 mM; p), or in serum-free medium alone (s). Values are
expressed as OD (3 1023) values; mean 6 SD of triplicate experiments.
Table II. Binding of NHS- and affinity-purified anti-b2GPI IgG
fractions to HUVEC incubated in the presence of b2GPI synthetic
peptides or of native b2GPI
Peptide
Concentrations
affinity-purified
M.B.
affinity-purified
B.A. IgG NHSa
P1
1000 mM 880 6 58b 700 6 51 182 6 71
800 mM 850 6 50 510 6 28 115 6 55
400 mM 430 6 58 380 6 35 194 6 51
200 mM 220 6 65 228 6 25 189 6 31
P8
1000 mM 385 6 60 250 6 58 181 6 54
800 mM 390 6 55 230 6 51 192 6 62
400 mM 280 6 65 200 6 65 173 6 32
200 mM 260 6 32 170 6 35 116 6 39
Native b2GPI
100 nM
1100 6 28 980 6 39 189 6 26
Without
b2GPI
188 6 32 179 6 47 216 6 38
a IgG preparations were used at the concentration of 100 mg/ml.
b Results are expressed as OD values (31023); mean 6 SD of triplicate experi-
ments.
Table III. Binding of NHS- and affinity-purified anti-b2GPI IgG
fractions, at serial protein concentrations, to HUVEC incubated in the
presence of either b2GPI synthetic peptides or native b2GPI
P1
(800 mM)
P8
(800 mM)
Native b2GPI
(100 nM)
affinity-purified M.B.
100 mg/ml 880 6 58a 375 6 51 981 6 41
50 mg/ml 650 6 55 210 6 55 700 6 52
25 mg/ml 421 6 50 180 6 28 506 6 39
12.5 mg/ml 215 6 42 151 6 35 302 6 42
6 mg/ml 118 6 24 129 6 27 200 6 34
3 mg/ml 105 6 32 115 6 38 162 6 36
affinity-purified B.A.
100 mg/ml 775 6 36 139 6 55 854 6 32
50 mg/ml 400 6 31 125 6 18 421 6 35
25 mg/ml 226 6 26 142 6 25 317 6 22
12.5 mg/ml 119 6 32 162 6 32 129 6 12
6 mg/ml 135 6 29 145 6 27 124 6 32
3 mg/ml 145 6 21 115 6 25 115 6 23
IgG NHS
100 mg/ml 122 6 14 116 6 31 132 6 22
a Results are expressed as OD values (31023); mean 6 SD of triplicate experi-
ments.
Table IV. E-selectin expression induced by anti-b2GPI Abs on
HUVEC incubated in the presence of either human purified b2GPI or
the synthetic peptides P1 and P8
HUVEC in Serum-Free Medium Incubated with
Serum-free
medium
alone
Native b2GPI
(100 nM)
P1
(800 mM)
P8
(800 mM)
GR1D5
(100 mg/ml)
113 6 50a 1080 6 130 1003 6 98 95 6 41
TM1B9
(100 mg/ml)
113 6 41 94 6 48 100 6 21 100 6 38
affinity-purified M.B.
(100 mg/ml)
93 6 35 1175 6 109 531 6 85 92 6 65
affinity-purified B.A.
(100 mg/ml)
90 6 24 990 6 59 700 6 99 85 6 42
NHS IgG
(100 mg/ml)
93 6 21 83 6 36 38 6 12 89 6 35
IL-1b
(50 U/ml)
1298 6 75 1283 6 98 1293 6 93 1282 6 105
Medium 76 6 36 71 6 31 65 6 22 78 6 35
a E-selectin expression was evaluated by a cell-ELISA as described in Materials
and Methods and expressed as OD values (31023); mean 6 SD of triplicate exper-
iments.
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as 25 mg/ml (data not shown). To confirm the specificity of this
phenomenon, HUVEC monolayers were also incubated in the
presence of high P1 and P8 concentrations alone: no E-selectin
expression was demonstrated even at peptide concentrations
higher (1600 mM) than those used in the experiments performed in
the presence of the anti-b2GPI Abs (data not shown).
To exclude that endothelial activation was, in part or entirely,
related to endotoxin contamination of the Ab preparations, parallel
control experiments were also performed in the presence of Poly-
myxin B (5 mg/ml; Sigma Chemical). The Ab-induced E-selectin
expression did not change. These findings suggest that endotoxin
contamination does not play a major role in Ab-mediated endo-
thelial activation (data not shown).
Ab binding to b2GPI synthetic peptides on endothelial cells up-
regulates IL-6 production
To evaluate whether E-selectin expression was associated with
other parameters of endothelial cell activation, we also investi-
gated whether GR1D5 mAb was able to induce IL-6 production
once bound to P1 adhered on HUVEC. Figure 4 shows that incu-
bation of GR1D5 mAb with serum-free HUVEC pretreated with
P1 up-regulated IL-6 secretion in an equivalent manner to mono-
layers incubated with purified human b2GPI. Endothelial cell
monolayers incubated with comparable amounts of P8 and GR1D5
mAb displayed levels of IL-6 production similar to those found in
control HUVEC cultures in serum free-medium alone. Control
TM1B9 mAb did not modify IL-6 background production under
any of the experimental conditions studied. Endothelial cell cul-
tures performed in the presence of human rIL-1b (50 U/ml) se-
creted high levels of IL-6 in the supernatants (1050 6 50 pg/ml,
mean values 6 SD of triplicate experiments).
Discussion
The binding of b2GPI to anionic structures seems to be a prereq-
uisite for allowing Ab recognition of the molecule (3, 36). Anti-
b2GPI Abs have been found to display low affinity binding and to
require increased Ag density such as that offered by b2GPI bound
to anionic structures (3, 5, 13). Alternatively, some authors have
reported that conformational changes occurring in bound b2GPI
might expose new epitopes eventually recognized by anti-b2GPI
Abs (18).
It has been demonstrated that a highly positively charged amino
acid sequence, Lys282-Asn-Lys-Glu-Lys-Lys287, located in the
fifth domain of b2GPI, is the PL-binding site involved in the bind-
ing to CL-coated plates (16, 17, 20). A single amino acid substi-
tution from Lys286 to Glu (mutant 1k) decreased the binding of
b2GPI to CL in a significant manner. Further substitutions—from
Lys286,287 to Glu286,287 (mutant 2k), from Lys284,287 to Glu284,287
(mutant 2ka), and from Lys284,286,287 to Glu284,286,287 (mutant
3k)—completely abolished the ability of b2GPI to bind to CL-
coated plates (20).
Our data show that recombinant wild-type b2GPI binds
HUVEC monolayers in a comparable manner to the native human
molecule. Bound b2GPI was recognized both by human IgM
mAbs and by affinity-purified polyclonal IgG anti-b2GPI Abs
from two patients with APS. Using the recombinant b2GPI mu-
tants, we demonstrated that the endothelial cell binding was com-
parable to that obtained in the CL-ELISA. Anti-b2GPI Ab binding
was significantly reduced when HUVEC were incubated with mu-
tant 1k, and it was completely abolished with 2k, 2ka, and 3k
mutants of b2GPI. These data suggest that b2GPI binds to human
endothelium by the major phospholipid-binding amino-acid se-
quence in the fifth domain. To confirm this observation, we used
two different peptides: P1, which contains the sequence Cys281-
Lys-Asn-Lys-Glu-Lys-Lys-Cys288 previously found to display PL-
binding activity, and P8, in which the substitution of Cys281 and
Cys288 with serine residues abolished PL-binding (17, 34). Both
peptides contain additional residues (GDKVSFF) that have been
reported to be an epitope for human monoclonal IgM anti-b2GPI
AbGR1D5 (34). The lack of reactivity of GR1D5 with HUVEC
incubated in the presence of P8 and its dose-dependent binding to
HUVEC incubated in the presence of serial concentrations of P1
further support the involvement of the PL-binding site in the ad-
hesion of b2GPI to the endothelium. Interestingly, two affinity-
purified polyclonal anti-b2GPI IgG fractions from patients with
APS were shown to recognize P1 adherent to endothelial mono-
layers. The latter finding is consistent with the presence in APS
sera of Ab specificities that react also with epitopes present in the
fifth domain of the molecule (34).
We have previously reported that although anti-b2GPI GR1D5
mAb binds to P1 when it is complexed with CL, it is unable to
react with microtiter plates coated with the same peptide in the
absence of CL (34). It is reasonable to conclude that the binding of
P1 to endothelial monolayers offers a suitable Ag density or the
optimal peptide conformation, as is found in CL-coated plates.
To detect anti-b2GPI mAb binding, endothelial monolayers, as
well as CL-coated plates (34), require a much higher peptide con-
centrations than that used with native b2GPI. These findings might
be consistent with the higher affinity displayed by the PL-binding
site in the native molecule than in the peptides and/or with the
higher avidity of the native b2GPI for anionic PL (or equivalent
endothelial structures) due to the presence of more than one PL-
binding site. On the other hand, the affinity and/or avidity of the
anti-b2GPI mAb itself could be higher for its epitope expressed on
the native molecule than on the peptide.
The binding between anti-b2GPI Abs and b2GPI (or the P1
peptide) anchored to endothelial membranes activates the cells as
demonstrated by the up-regulation of E-selectin expression and
IL-6 secretion. These findings confirm previous data on endothelial
FIGURE 4. Endothelial IL-6 secretion by HUVEC incubated in the
presence of b2GPI or synthetic peptides and anti-b2GPI mAbs (GR1D5
and TM1B9). IL-6 secretion was evaluated in supernatants of HUVEC
cultured in serum-free medium (h) or in the presence of b2GPI (100 nM;
o), P1 (800 mM; p), or P8 (800 mM; s). IL-6 levels are expressed as mean
pg/ml 6 SD of triplicate determinations.
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cell activation obtained with whole IgG fractions from APS sera
(32) or with both human monoclonal and polyclonal affinity-pu-
rified IgG anti-b2GPI Abs (27, 30). In addition, our results indicate
that a linear amino acid sequence of the fifth domain of b2GPI,
which includes the major phospholipid-binding site, is one of the
epitopes for anti-b2GPI Abs that bound to human endothelial cells.
It has been suggested that the membrane binding of IgG aPL Abs
might affect cell activation through the involvement of FcgR (37).
The demonstration that anti-b2GPI IgM mAbs induce endothelial
cell activation, in the presence of peptide P1, rules out this
possibility.
b2GPI is a normal plasma glycoprotein whose endothelial cell
binding might represent a physiologic event related, for example,
to the cell uptake of lipid-carrying proteins (23). Accordingly,
b2GPI adhesion to endothelium has been described even in normal
placental vessels in in vivo studies (33, 38). Recently, Takeya et al.
(39) demonstrated that anti-b2GPI mAbs exert lupus anticoagulant
activity by enhancing the binding of b2GPI to phospholipids. Such
an effect may account for the stabilization of the binding of b2GPI
also to endothelial cell membranes and for the changing of a phys-
iologic binding into a pathologic one. Moreover, the clustering
effect of anti-b2GPI Abs on endothelial-adhered b2GPI molecules
may also be the molecular means by which APS sera perturb the
endothelial function in vitro.
In conclusion, our results are consistent with a model of b2GPI
acting as an endothelial cell target Ag for circulating anti-b2GPI
Abs in APS. b2GPI binds endothelial cell membranes through the
predicted PL-binding site; its binding is apparently able to trap and
increase Ag density and/or to induce conformational changes suit-
able for Ab binding. The final event is represented by functional
changes in the endothelium that might be instrumental in promot-
ing a procoagulant tendency. However, despite high levels of cir-
culating autoantibodies and such in vitro findings, there are no
evidences for an in vivo Ig deposition in the patients’ vascular
lesions (40). In this regard, it is useful to point out that anti-b2GPI
Abs have been characterized as low affinity Abs (13, 41). There-
fore, in vitro experimental conditions might offer the best Ag den-
sity and the optimal Ab binding that could be affected in vivo by
detachment (or engulfment) of the Ab or the b2GPI/anti-b2GPI
complexes from endothelial membranes. In such a way, endothe-
lial binding could induce the activation state without a huge Ig
deposition detectable by standard immunohistochemical analysis.
Thrombosis would require a second triggering factor, thus explain-
ing why patients with persistent serum autoantibodies display clot-
ting events only occasionally and in the absence of detectable Ig
deposits.
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